Bayer: Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 With Phase II Combination Study in First-Line Patients With Advanced Colorectal Cancer
October 16, 2026
October 16, 2026
WHIPPANY, New Jersey, Oct. 16 [Category: BizPharmaceuticals] -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, posted the following news:
* * *
Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 with Phase II Combination Study in First-Line Patients with Advanced Colorectal Cancer
* First patient dosed in global Phase II study evaluating VVD-214, an oral Werner helicase (WRN) . . .
* * *
Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 with Phase II Combination Study in First-Line Patients with Advanced Colorectal Cancer
* First patient dosed in global Phase II study evaluating VVD-214, an oral Werner helicase (WRN) . . .